A 2026 review article synthesized existing evidence regarding glucagon-like peptide-1 receptor agonists and dual agonists (GLP-1s) as pharmacologic treatments for obesity and cardiometabolic disease in individuals with spinal cord injury (SCI). Given the disproportionate burden of neurogenic obesity and associated cardiometabolic risk in SCI, alongside limited effectiveness of lifestyle interventions alone, the review emphasized the potential clinical relevance of GLP-1 therapies, which have demonstrated substantial weight loss and cardiometabolic improvements in the general population. The review integrated data from phase 3 trials and case series, including a controlled case series of semaglutide in five sedentary adults with chronic SCI that reported average body weight reductions of 6 kg, notable decreases in fat mass and visceral adiposity, and modest improvements in glycemic control. Additionally, a single case report described a chronic C6 motor-complete SCI patient achieving...

READ MORE→

A 2020 review describes skin staining as an uncommon but recognized adverse effect of intravenous (IV) iron that occurs following extravasation and may be permanent. Clinical trial data cited in the article report skin discoloration rates with IV iron preparations ranging from 0.68% to 1.3%, while postmarketing surveillance suggests lower reported rates, acknowledging likely underreporting. A review of the French pharmacovigilance database (2000 to 2016) identified 51 cases of cutaneous pigmentation associated with iron; reports from the Australian adverse event database (2014 to 2019) documented 27 cases with ferric carboxymaltose and 8 cases with iron polymaltose, while no cases with iron sucrose were documented in this database. The authors emphasize that skin staining is cosmetically significant, warrants informed consent, and is best prevented through appropriate cannulation, close monitoring, and immediate cessation of infusion if extravasation is suspected. [1] However, an...

READ MORE→

A 2016 systematic review and meta-analysis evaluated pharmacist-led medication reconciliation at hospital transitions, including 17 studies involving 21,342 adults. Interventions commonly included obtaining or confirming an accurate medication history, reconciling medications at discharge, providing discharge counseling or documentation, and conducting postdischarge telephone calls or home visits. Most included studies featured multiple transitions. Compared with usual care, these programs reduced all-cause readmissions by 19% (relative risk [RR], 0.81; 95% confidence interval [CI], 0.70-0.95) and medication-related adverse drug event hospital revisits by 67% (RR, 0.33; 95% CI, 0.20-0.53). The reduction in readmissions was significant during earlier follow-up, generally within 30 days (RR, 0.77; 95% CI, 0.60-0.98), but not during longer follow-up (RR, 0.83; 95% CI, 0.68-1.06), suggesting that the benefit may be greatest shortly after discharge. However, substantial heterogeneity, in...

READ MORE→

According to 2026 American Academy of Pediatrics (AAP) and American Society of Pediatric Hematology-Oncology clinical guidance on iron deficiency and iron deficiency anemia (IDA) in infants, children, and adolescents, intravenous (IV) iron sucrose is FDA-approved for pediatric patients over 2 years of age, carries no black box warning, and requires no test dose, distinguishing it from low-molecular-weight iron dextran. The guidance specifies a maximum FDA-approved single infusion dose of 100 mg for initial treatment and 300 mg for maintenance, administered undiluted over 5 minutes or diluted over 30 to 90 minutes. IV iron is recommended for children with refractory or persistent IDA after at least 3 months of oral therapy, particularly those with elevated hepcidin from chronic inflammatory conditions or intestinal malabsorption, and referral to a pediatric specialty center experienced in parenteral iron is advised. The guidance underscores that appropriate monitoring with staff prep...

READ MORE→

According to a 2017 American College of Obstetricians and Gynecologists (ACOG) guidance document on postpartum hemorrhage, fibrinogen concentrates are specifically approved for treating acute bleeding in patients with congenital fibrinogen deficiency. Nevertheless, limited data are available regarding the use of prothrombin complex concentrates (PCCs) and fibrinogen concentrates in postpartum hemorrhage (PPH) and disseminated intravascular coagulation. Consequently, their use is advised only after several rounds of standard massive transfusion agents have been administered and in consultation with an expert in massive hemorrhage. The guidance does not provide recommendations for specific fibrinogen concentrate products, including Fibryga, or product-specific dosing for PPH following vaginal or cesarean delivery. [1] Several review articles have evaluated fibrinogen concentrate for PPH, with evidence suggesting that fibrinogen <200 mg/dL is associated with progression to severe P...

READ MORE→